Cargando…
STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
Anaplastic lymphoma kinase (ALK) rearrangement occurs in 5% to 8% of patients with non-small cell lung cancer (NSCLC). More than 90 different ALK fusion partners have been discovered in NSCLC patients, and ALK tyrosine kinase inhibitors (TKIs) such as crizotinib and alectinib have achieved tumor res...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417525/ https://www.ncbi.nlm.nih.gov/pubmed/34490099 http://dx.doi.org/10.3389/fonc.2021.700341 |
_version_ | 1783748392583692288 |
---|---|
author | Feng, Chunlai Zhou, Rong Liu, Feng Wang, Tingting Liu, Sisi Shao, Yang |
author_facet | Feng, Chunlai Zhou, Rong Liu, Feng Wang, Tingting Liu, Sisi Shao, Yang |
author_sort | Feng, Chunlai |
collection | PubMed |
description | Anaplastic lymphoma kinase (ALK) rearrangement occurs in 5% to 8% of patients with non-small cell lung cancer (NSCLC). More than 90 different ALK fusion partners have been discovered in NSCLC patients, and ALK tyrosine kinase inhibitors (TKIs) such as crizotinib and alectinib have achieved tumor responses in patients with advanced ALK-positive NSCLC. Here, we report the case of a patient with an advanced NSCLC carrying a novel serine/threonine kinase 3 (STK3)-ALK rearrangement, which was identified by targeted next-generation sequencing (NGS) and was confirmed by RNA sequencing. Anti-ALK immunohistochemistry (IHC) staining also revealed the high expression of ALK. The patient benefitted from alectinib treatment after experiencing crizotinib resistance and achieved an overall response to TKI of over 14 months. At the timepoint of submission of this manuscript, this patient is still receiving alectinib treatment with a good tolerance. This study provides meaningful insights into the potential treatment option for NSCLC patients with brain metastases harboring STK3-ALK fusions and highlights the advantages of NGS in rapidly identifying novel molecular targets. |
format | Online Article Text |
id | pubmed-8417525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84175252021-09-05 STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report Feng, Chunlai Zhou, Rong Liu, Feng Wang, Tingting Liu, Sisi Shao, Yang Front Oncol Oncology Anaplastic lymphoma kinase (ALK) rearrangement occurs in 5% to 8% of patients with non-small cell lung cancer (NSCLC). More than 90 different ALK fusion partners have been discovered in NSCLC patients, and ALK tyrosine kinase inhibitors (TKIs) such as crizotinib and alectinib have achieved tumor responses in patients with advanced ALK-positive NSCLC. Here, we report the case of a patient with an advanced NSCLC carrying a novel serine/threonine kinase 3 (STK3)-ALK rearrangement, which was identified by targeted next-generation sequencing (NGS) and was confirmed by RNA sequencing. Anti-ALK immunohistochemistry (IHC) staining also revealed the high expression of ALK. The patient benefitted from alectinib treatment after experiencing crizotinib resistance and achieved an overall response to TKI of over 14 months. At the timepoint of submission of this manuscript, this patient is still receiving alectinib treatment with a good tolerance. This study provides meaningful insights into the potential treatment option for NSCLC patients with brain metastases harboring STK3-ALK fusions and highlights the advantages of NGS in rapidly identifying novel molecular targets. Frontiers Media S.A. 2021-08-19 /pmc/articles/PMC8417525/ /pubmed/34490099 http://dx.doi.org/10.3389/fonc.2021.700341 Text en Copyright © 2021 Feng, Zhou, Liu, Wang, Liu and Shao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Feng, Chunlai Zhou, Rong Liu, Feng Wang, Tingting Liu, Sisi Shao, Yang STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report |
title | STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report |
title_full | STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report |
title_fullStr | STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report |
title_full_unstemmed | STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report |
title_short | STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report |
title_sort | stk3-alk, a novel alk rearrangement in non-small cell lung cancer with sensitivity to tyrosine kinase inhibitors: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417525/ https://www.ncbi.nlm.nih.gov/pubmed/34490099 http://dx.doi.org/10.3389/fonc.2021.700341 |
work_keys_str_mv | AT fengchunlai stk3alkanovelalkrearrangementinnonsmallcelllungcancerwithsensitivitytotyrosinekinaseinhibitorsacasereport AT zhourong stk3alkanovelalkrearrangementinnonsmallcelllungcancerwithsensitivitytotyrosinekinaseinhibitorsacasereport AT liufeng stk3alkanovelalkrearrangementinnonsmallcelllungcancerwithsensitivitytotyrosinekinaseinhibitorsacasereport AT wangtingting stk3alkanovelalkrearrangementinnonsmallcelllungcancerwithsensitivitytotyrosinekinaseinhibitorsacasereport AT liusisi stk3alkanovelalkrearrangementinnonsmallcelllungcancerwithsensitivitytotyrosinekinaseinhibitorsacasereport AT shaoyang stk3alkanovelalkrearrangementinnonsmallcelllungcancerwithsensitivitytotyrosinekinaseinhibitorsacasereport |